lithium + fluvoxamine

Lithium + fluvoxamine is a combination of two pharmaceutical agents used primarily in the management of mood and anxiety disorders, particularly in cases where monotherapy has proven insufficient. Lithium is a classic mood stabilizer commonly used for bipolar disorder, while fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) indicated for depression and obsessive-compulsive disorder. The combination may be considered in treatment-resistant depression or bipolar depression to enhance therapeutic efficacy. Lithium acts by modulating neurotransmitter signaling and second messenger systems, while fluvoxamine increases synaptic serotonin levels by inhibiting its reuptake into presynaptic neurons. Clinical studies suggest that the combination can provide greater improvement in depressive symptoms than either agent alone; however, it requires careful monitoring due to potential side effects such as somnolence, tremor, agitation, insomnia, and an increased risk of serotonin syndrome[1][4][5]. Pharmacokinetic interactions between these drugs are generally minimal—lithium does not significantly alter plasma concentrations or pharmacokinetics of fluvoxamine—but additive pharmacodynamic effects necessitate close clinical supervision[1][3][4].